The primary outcome of interest was overall PDAC survival in patients who used beta blockers compared to patients who did not use beta blockers in the 6 months before cancer diagnosis. Survival time was defined as the time from the diagnosis of PDAC to death. Since pancreatic cancer has a high mortality rate, mortality was expected to reflect pancreatic cancer-related survival, as has been reported in other studies using SEER17. As a secondary analysis, we performed a subgroup analysis of patients with PDAC who had continuous Part D Medicare coverage in the 6 months before and after diagnosis to determine the overall survival effect of beta blocker use surrounding PDAC diagnosis.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.